BMC Pharmacology and Toxicology is calling for submissions for the Collection on Small molecule therapy.

Small molecule therapy encompasses a diverse range of pharmacological agents designed to modulate biological processes at the molecular level. These compounds have revolutionized the treatment landscape for various diseases, including cancer, cardiovascular disorders, and neurodegenerative conditions. The ongoing exploration of small molecules, their mechanisms of action, and their interactions with cellular pathways has opened new avenues for therapeutic development. This Collection aims to highlight recent advancements and innovative strategies in small molecule therapy, focusing on the design, synthesis, and application of these agents to treat various diseases.

The development of highly specific small molecule therapeutic compounds has improved treatment efficacy while minimizing toxicity, and recent breakthroughs in drug delivery systems and formulation techniques have enabled targeted therapies that maximize therapeutic benefit while reducing side effects. Additionally, advances in computational methods, including machine learning and AI-guided drug design, when accompanied by real-world validation of molecular targets, are a promising avenue of research in this field.

To showcase advances in the development of small molecule therapies, topics for this collection include but are not limited to:

Target specificity in small molecule design

Assessment of pre-clinical and clinical toxicity and long-term effects

Drug-drug interactions in small molecule therapy

Innovations in drug delivery and formulation

Computational and AI-guided small molecule drug design

Validation of in silico studies with in vitro and in vivo data

All manuscripts submitted to this journal, including those submitted to collections and special issues, are assessed in line with our editorial policies and the journal’s peer review process. Reviewers and editors are required to declare competing interests and can be excluded from the peer review process if a competing interest exists.

BMC Pharmacology and Toxicology is calling for submissions to our Collection on Pharmacogenomics, a rapidly evolving field examining the influence of genetic variations on individual responses to drugs. By integrating pharmacology and genomics, this discipline aims to minimize adverse effects of drugs, optimize drug efficacy and enhance therapeutic outcomes. Understanding these genetic factors enables clinicians to tailor medication choices based on a patient’s unique genetic makeup, paving the way for more personalized and effective treatment plans. As the landscape of drug development evolves, pharmacogenomics offers significant insights into drug efficacy, safety, and the potential for individualized medicine.

The significance of pharmacogenomics lies in its transformative potential for precision medicine. Recent advancements have illuminated the role of genetic polymorphisms in drug metabolism, leading to improved strategies for predicting drug responses and mitigating adverse effects. Research has demonstrated that leveraging pharmacogenomic information can enhance treatment efficacy for various conditions, including cancer, cardiovascular diseases, and psychiatric disorders. As healthcare systems increasingly adopt personalized medicine approaches, pharmacogenomics will play a crucial role in optimizing therapeutic regimens and improving patient outcomes.

Continued research in pharmacogenomics holds the promise of uncovering novel genetic markers that influence drug response and safety profiles. Future advancements may lead to the development of comprehensive genomic databases that facilitate the integration of pharmacogenomic data into routine clinical practice. As our understanding of human genetics deepens, we may also witness the emergence of innovative therapeutic strategies that harness genetic insights to tailor drug therapies more effectively.

Potential topics for submission include but are not limited to:

Genetic variations and drug response

Pharmacogenomics in precision medicine

Adverse effects and genetic predictors

Immunogenicity in drug therapies

This Collections supports and amplifies research related to SDG 3: Good Health and Well-being.

All manuscripts submitted to this journal, including those submitted to collections and special issues, are assessed in line with our editorial policies and the journal’s peer review process. Reviewers and editors are required to declare competing interests and can be excluded from the peer review process if a competing interest exists.